Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12008/53300

Título:

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Otros títulos:

Coordinador:

Director:

Compilador:

Autor:

Martínez-Cordero, Humberto
Peña, Camila
Schutz, Natalia Paola
Bove, Virginia
Villano, Fiorella
Beltrán, Cecilia
Donoso, Javiera
López-Vidal, Hernán
Roa Salinas, Macarena Alejandra
Soto, Pablo
Ochoa, Paola
Duarte, Patricio
Riva, Eloísa

Tutor:

Tipo de documento:

Artículo

Editor:

Palabras clave:

Descriptores:

PERSONA DE MEDIANA EDAD
PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA
BORTEZOMIB
CICLOFOSFAMIDA
DEXAMETASONA
MIELOMA MÚLTIPLE
PRONÓSTICO
TALIDOMIDA
RESULTADO DEL TRATAMIENTO
USOS TERAPÉUTICOS
QUIMIOTERAPIA
EPIDEMIOLOGÍA

Año de publicación:

2023

Contenido:

Resumen:

PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.

Descripción:

Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, Sanof

metadata.articulos.dc.description.uri:

Editorial:

American Society of Clinical Oncology

EN:

JCO Global Oncology. 2023;9

Financiadores:

Citación:

Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p.

Citación:

metadata.articulos.cc.license.name:

ISBN:

e-ISBN:

ISSN:

ISMN:

Otros identificadores:

Cobertura geográfica:

AMÉRICA LATINA

Cobertura temporal:

Departamento académico:

Grupo de investigación:

Licencia:

Licencia Creative Commons Atribución (CC - By 4.0)

Colecciones:

Publicaciones Académicas y Científicas
FicherosDescripciónTamañoFormato
Patients Age 40 Years and Younger With Multiple Myeloma.pdf Patients Age 40 Years and Younger With Multiple Myeloma 3.28 MB Adobe PDF
Mostrar el registro Dublin Core completo del ítem